According to the Complaint, OvaScience is a life science company that engages in the discovery, development, and commercialization of new treatments for infertility. The Company develops various fertility treatment options purported to enhance egg health and revolutionize in vitro fertilization ("IVF"). The Company's AUGMENT treatment, designed to improve the energy and health of the woman's eggs by using mitochondria from a woman's egg precursor cells ("EggPCs"), is available in certain IVF clinics in select international regions.
The Complaint alleges that in violation of the Securities Act, Defendants negligently issued untrue statements of material facts and omitted to state material facts required to be stated from the Registration Statement and incorporated Offering Materials that the Company filed with the SEC in support of the Offering.
On May 23, 2016, the Court issued an Order remanding this case to State Court.
Company & Securities Information
Defendant: OvaScience, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: OVAS
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Heather Carlson, et al. v. Ovascience, Inc., et al.